{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:09:17Z","timestamp":1773148157764,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The aim of this study was to explore the prognostic value of total metabolic tumor volume (TMTV) at baseline\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT in patients diagnosed with peripheral T-cell lymphoma (PTCL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Eighty-four newly diagnosed PTCL patients who underwent baseline\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT prior to treatment between March 2009 and January 2019 were enrolled in this retrospective study. The FDG-avid lesions in each patient were segmented using semiautomated software to calculate the maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG) values using the boundaries of voxels presenting with the 41% SUVmax threshold method. Progression-free survival (PFS) and overall survival (OS) were used as end points to evaluate patient prognosis. The log-rank test and Cox regression analyses were used to evaluate PFS and OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ROC curve analysis indicated an ideal TMTV cut-off value of 228.8\u00a0cm\n                      <jats:sup>3<\/jats:sup>\n                      . During the 4\u2013131\u00a0months (29.2\u2009\u00b1\u200928.5\u00a0months) follow-up period, high TMTV was significantly associated with worse PFS and OS. TMTV and the international peripheral T-cell lymphoma project score (IPTCLP) were independent predictors of PFS and OS with multivariate analysis. The combination of TMTV and the IPTCLP may provide significantly better risk substratification in PFS and OS of PTCL patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both TMTV and IPTCLP are independent predictors of PTCL patient survival outcomes. Moreover, the combination of TMTV and IPTCLP improved patient risk stratification and may contribute to personalized therapeutic regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-020-00698-y","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T07:03:39Z","timestamp":1600844619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)"],"prefix":"10.1186","volume":"10","author":[{"given":"Chong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"1","key":"698_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/j.seminhematol.2013.11.003","volume":"51","author":"P Gaulard","year":"2014","unstructured":"Gaulard P, de Leval L. Pathology of peripheral T-cell lymphomas: where do we stand? Semin Hematol. 2014;51(1):5\u201316.","journal-title":"Semin Hematol"},{"issue":"12","key":"698_CR2","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1182\/blood-2008-07-077982","volume":"112","author":"ES Jaffe","year":"2008","unstructured":"Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112(12):4384\u201399.","journal-title":"Blood"},{"issue":"9","key":"698_CR3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0524","volume":"23","author":"K Laribi","year":"2018","unstructured":"Laribi K, Alani M, Truong C, Baugier de Materre A. Recent advances in the treatment of peripheral T-cell lymphoma. Oncologist. 2018;23(9):1039\u201353.","journal-title":"Oncologist"},{"issue":"7","key":"698_CR4","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474\u20139.","journal-title":"Blood"},{"issue":"11","key":"698_CR5","doi-asserted-by":"crossref","first-page":"239A","DOI":"10.1182\/blood.V106.11.239.239","volume":"106","author":"JM Vose","year":"2005","unstructured":"Vose JM. International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood. 2005;106(11):239A.","journal-title":"Blood"},{"issue":"2","key":"698_CR6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdq359","volume":"22","author":"G Gutierrez-Garcia","year":"2011","unstructured":"Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Mart\u00ednez A, Villamor N, Ghita G, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22(2):397\u2013404.","journal-title":"Ann Oncol"},{"issue":"2","key":"698_CR7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-014-2188-8","volume":"94","author":"P Xu","year":"2015","unstructured":"Xu P, Yu D, Wang L, Shen Z, Zhao W. Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients. Ann Hematol. 2015;94(2):239\u201347.","journal-title":"Ann Hematol"},{"issue":"1","key":"698_CR8","doi-asserted-by":"crossref","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","volume":"14","author":"B Guo","year":"2019","unstructured":"Guo B, Tan X, Ke Q, Cen H. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis. PLoS ONE. 2019;14(1):e0210224.","journal-title":"PLoS ONE"},{"issue":"14","key":"698_CR9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987\u201394.","journal-title":"N Engl J Med"},{"key":"698_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"698_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/annonc\/mdw011","volume":"27","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27(4):719\u201324.","journal-title":"Ann Oncol"},{"issue":"2","key":"698_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","volume":"3","author":"N Mehta-Shah","year":"2019","unstructured":"Mehta-Shah N, Ito K, Bantilan K, Moskowitz AJ, Sauter C, Horwitz SM, et al. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood Adv. 2019;3(2):187\u201397.","journal-title":"Blood Adv"},{"issue":"21","key":"698_CR13","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","volume":"23","author":"H Schoder","year":"2005","unstructured":"Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(21):4643\u201351.","journal-title":"J Clin Oncol"},{"issue":"3","key":"698_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/hon.782","volume":"24","author":"M Hutchings","year":"2006","unstructured":"Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006;24(3):146\u201350.","journal-title":"Hematol Oncol"},{"issue":"2","key":"698_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2214\/AJR.09.3665","volume":"195","author":"J Feeney","year":"2010","unstructured":"Feeney J, Horwitz S, Gonen M, Schoder H. Characterization of T-cell lymphomas by FDG PET\/CT. AJR Am J Roentgenol. 2010;195(2):333\u201340.","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"698_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.clml.2018.06.022","volume":"18","author":"R Gurion","year":"2018","unstructured":"Gurion R, Bernstine H, Domachevsky L, Michelson C, Raanani P, Vidal L, et al. Utility of PET-CT for evaluation of patients with peripheral T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(10):687\u201391.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"698_CR17","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402\u20138.","journal-title":"Blood"},{"issue":"16","key":"698_CR18","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472\u20139.","journal-title":"J Clin Oncol"},{"issue":"25","key":"698_CR19","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"Vose J, Armitage J, Weisenburger D, International TCLP","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"18","key":"698_CR20","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood"},{"issue":"4","key":"698_CR21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.blre.2007.03.001","volume":"21","author":"O Tournilhac","year":"2007","unstructured":"Tournilhac O, Delarue R, Gaulard P. Peripheral T-cell lymphomas. Blood Rev. 2007;21(4):201\u201316.","journal-title":"Blood Rev"},{"issue":"1","key":"698_CR22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T Rudiger","year":"2002","unstructured":"Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13(1):140\u20139.","journal-title":"Ann Oncol"},{"issue":"7","key":"698_CR23","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00259-019-04309-4","volume":"46","author":"QA Shagera","year":"2019","unstructured":"Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, et al. Prognostic value of metabolic tumour volume on baseline (18)F-FDG PET\/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging. 2019;46(7):1417\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"30","key":"698_CR24","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618\u201326.","journal-title":"J Clin Oncol"},{"issue":"1","key":"698_CR25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2012.09.011","volume":"37","author":"MK Song","year":"2013","unstructured":"Song MK, Chung JS, Shin HJ, Moon JH, Ahn JS, Lee HS, et al. Clinical value of metabolic tumor volume by PET\/CT in extranodal natural killer\/T cell lymphoma. Leuk Res. 2013;37(1):58\u201363.","journal-title":"Leuk Res"},{"key":"698_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.01.010","volume":"42","author":"MK Song","year":"2016","unstructured":"Song MK, Yang DH, Lee GW, Lim SN, Shin S, Pak KJ, et al. High total metabolic tumor volume in PET\/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. Leuk Res. 2016;42:1\u20136.","journal-title":"Leuk Res"},{"issue":"7","key":"698_CR27","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","volume":"45","author":"H Ilyas","year":"2018","unstructured":"Ilyas H, Mikhaeel NG, Dunn JT, Rahman F, M\u00f8ller H, Smith D, et al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"698_CR28","first-page":"9746716","volume":"2020","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang X, Qin H, Zhao Z, Li J, Zhang B, et al. Prognostic values of baseline (18)F-FDG PET\/CT in patients with peripheral T-cell lymphoma. Biomed Res Int. 2020;2020:9746716.","journal-title":"Biomed Res Int"},{"issue":"23","key":"698_CR29","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.7150\/jca.30415","volume":"10","author":"J Xia","year":"2019","unstructured":"Xia J, Zhu HY, Liang JH, Ding CY, Wang L, Wu W, et al. The prognostic role of 18F-FDG PET\/CT baseline quantitative metabolic parameters in peripheral T-cell lymphoma. J Cancer. 2019;10(23):5805\u201311.","journal-title":"J Cancer"},{"issue":"8","key":"698_CR30","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","volume":"60","author":"SF Barrington","year":"2019","unstructured":"Barrington SF, Meignan MA. Time to prepare for risk adaptation in lymphoma by standardising measurement of metabolic tumour burden. J Nucl Med. 2019;60(8):1096\u2013102.","journal-title":"J Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-020-00698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-020-00698-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-020-00698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T19:28:41Z","timestamp":1632338921000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-020-00698-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1186\/s13550-020-00698-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-38884\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-38884\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-38884\/v2","asserted-by":"object"}]},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"27 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}